Research has indicated that the inflammasome inhibitor (NLRP2/AIM-3-IN-21) exhibited significant therapeutic potential in psoriasis, and effectively suppressed the expression levels of NLRP3, IL-17A, and AIM2 in psoriatic skin lesion tissues (21). The gene discussed is IL17A; the disease is psoriasis.